Amylyx Pharmaceuticals

IPO

Amylyx Pharmaceuticals is a healthcare company in Cambridge, United States, founded in 2013. It has raised $197.3M across 4 rounds, most recently a $135.0M Series C in July 2021.

Home | Amylyx

Employees
51–200
Founded
2013
Business Model
B2B
Website
amylyx.com
Total Funding
$197.3M
Last Round
$135.0M Series CJul 2021
Rounds
4
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 4 funding rounds and 4 investors for this company. The full record is or through the API.

About

Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company founded in 2013 by Josh Cohen and Justin Klee at Brown University, headquartered in Cambridge, Massachusetts. The company is dedicated to developing novel therapies for diseases with high unmet needs, with a pipeline spanning ALS, Wolfram syndrome, post-bariatric hypoglycemia, and congenital hyperinsulinism. Amylyx completed its IPO on NASDAQ in January 2022 and has advanced multiple investigational therapies through Phase 2 and Phase 3 clinical trials, backed by rigorous science and deep engagement with patient communities.

Summary

It lists 51–200 employees. It has raised $197.3M in total across 4 rounds, most recently a $135.0M Series C round in Jul 2021. Investors include Morningside Group, Viking Global and Bain Capital Life Sciences.

Tech & App Stack

8 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Data from Indexed.vcUpdated
Series CSeries CJul 2021
$135.0M

Sign up to see all 4 events

Funding: Series B through Series C. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Amylyx Pharmaceuticals on Indexed.vc
<a href="https://indexed.vc/companies/amylyx-pharmaceuticals"><img src="https://indexed.vc/api/badge/company/amylyx-pharmaceuticals" alt="Amylyx Pharmaceuticals on Indexed.vc" width="260" height="76" /></a>